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A GO game can enhance mental health, but its effects on Alzheimer Disease (AD)
remains unknown. To address the issue, 147 AD patients were randomly assigned
into control (without GO-game intervention), Short-time GO-Game Intervention (SGGI,
1 h daily) and Long-time GO-game Intervention (LGGI, 2 h daily) groups. After 6-month
follow-up, the game reduced the mean score of Montgomery-Asberg Depression Rating
Scales (MADRS) of 4.72 (95% CI, 0.69 to 9.12) and Hospital Anxiety and Depression
Scale (HADS) of 1.75 (95% CI, 0.17–3.68), and increased the mean score of Global
Assessment of Functioning (GAF) of 4.95 (95% CI, −1.37–9.18) and RAND-36 of 4.61
(95% CI, −2.75–11.32) (P < 0.05 via controls). A GO-game intervention improved 9
of 11 items of KICA-dep (Kimberley Indigenous Cognitive Assessment of Depression).
Meanwhile, serum levels of brain derived neurotrophic factor (BDNF) were higher in SGGI
and LGGI groups (24.02 ± 7.16 and 28.88 ± 4.12 ng/ml respectively, P = 0.051) than
those in controls (17.28 ± 7.75 ng/ml) (P < 0.001). The serum levels of BDNF showed
a negative relation with MADRS and a positive relation with RAND-36 (P < 0.01). A
GO-game intervention ameliorates AD manifestations by up-regulating BDNF levels.
Keywords: Alzheimer’s disease, brain-derived neurotrophic factor, GO game, Montgomery-Asberg Depression
Rating Scale, RAND-36
Introduction
Alzheimer’s disease (AD) is one leading cause of dementia and aﬀects more than 35 million people
in the world (Gregori et al., 2015; Hamilton et al., 2015). AD is a kind of neurodegenerative
disorder and mainly characterized by extracellular senile plaques and intracellular neuroﬁbrillary
tangles. The high incidence and ﬁnancial global burden of AD manifestations greatly reduce
the quality of elderly life. However, the etiology of AD is complex and medicine therapy is still
the mainstay for AD patients. Cholinesterase inhibitor and memantine (1-amino-3,5-dimethyl-
adamantane) are often used for the conventional therapy of AD patients (Ahn et al., 2014; Dysken
et al., 2014; Evans et al., 2014). However, all the medicine has signiﬁcant side eﬀects. Cholinesterase
inhibitors cause the side eﬀects, such as bradycardia (Leikin et al., 2014), hypotension (van Beek
et al., 2010), and low intraocular pressure (Sawada et al., 1971). Memantine causes common
adverse eﬀects, such as confusion, dizziness, drowsiness, headache, insomnia and hallucinations,
and some less common adverse eﬀects including vomiting, anxiety, hypertonia, cystitis and libido
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(Rossom et al., 2004; Jain et al., 2008). Furthermore, it can induce
reversible neurological impairment in sclerosis (an inﬂammatory
disease in the brain and spinal cord) patients, resulting in the
halt of a clinical trial (Villoslada et al., 2009). High cost of the
medicine and serious unwanted adverse eﬀects, have limited its
utilization. Therefore, it is highly demanded to explore low-cost
non-pharmaceutical method for AD patients.
Brain exercises are widely known approaches to prevent
dementia, increase neurogenesis and protect neurons (Gatz,
2005). Physicians often advise the elderly to engage in a mentally
challenging activity to reduce dementia risk. The elderly spend
time solving crossword puzzles, anagrams and ﬁgural logic
puzzles, and may feel well if the activities are both challenging
and successfully completed. More education has been found to
be related to a lower incidence of AD. Typically, the risk of
AD is 2–4 times higher in the persons with less education than
those with more education (Qiu et al., 2001). On the other hand,
the elderly participate in leisure activities, especially for mental
stimulation, will also have a lower incidence of AD (Provencher
et al., 2009). In addition, longitudinal studies have showed older
adults have less dementia if they participate in intellectually
challenging activity (Hultsch et al., 1999).
The GO game, a kind of Chinese chesses, has been practiced
as a brain activity for more than 5000 years. Playing the game
involves many aspects of cognition and improves mental health
(Kim et al., 2014). A GO game involves the changes associated
with many cognitive functions, including learning, abstract
reasoning, and self-control, which facilitate cognitive behavioral
therapy (Lee et al., 2010). However, the functional role of a GO
game in AD patients remains elusive. Furthermore, brain derived
neurotrophic factor (BDNF) is often deﬁcient in AD patients
or animal AD models (Voineskos et al., 2011; Lee et al., 2012;
Boiocchi et al., 2013). BDNF protects cerebral cortical neurons
against beta-amyloid 25–35 (the major AD toxic peptide) and
inhibits beta-amyloid 25–35 aggregation in the brain (Xiao et al.,
2010; Zhang et al., 2012). AGO gamemay ameliorate AD patients
by aﬀecting the levels of BDNF since BDNF plays a critical
role in learning and memory functions (Fan et al., 2014). Thus,
we explored the functions of a GO game in AD patients and
measured BDNF levels in AD patients before and after the study.
Materials and Methods
Participants
All the protocols were approved by the Institutional Ethics
Committee from the Fourth Aﬃliated Hospital of China Medical
University and conducted in accordance with the Declaration of
Helsinki (Palacios, 2013). All subjects were Han Chinese from
Shenyang city (China). An informed consent was obtained either
from each subject or from his or her guardian. All AD patients
were diagnosed with NINCDS-ADRDA (National Institute of
Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association) criteria
according to a previous report (Tamaoka, 2011). All familial
cases of AD were excluded in this study. The patients were
excluded if they met any of the following criteria: (1) a history of
suicidal behavior; (2) substance abuse; (3) verbal communication
diﬃculty; (4) a family history of AD; (5) brain injury or other
brain disorders; (6) disliking playing a GO game. From July
7th, 2014 to January 8th, 2015, a total of 147 AD patients were
recruited at the Fourth Aﬃliated Hospital of China Medical
University (Shenyang, China).
Study Design
After scanning all AD patients, 147 patients were eligible to
enter designated 6-month follow-up (Figure 1). A randomized
and controlled trial was conducted using three groups: control
(without GO-game intervention, n = 49), short-time GO-game
intervention (SGGI, 1 h daily, n = 49) and long-time GO-
game intervention (LGGI, 2 h daily, n = 49) groups. The three
groups have the similar gender ratio, age, BMI (body mass index,
the ratio of weight (kg) to height in meters squared), years of
education, alcohol drinking, cigarette smoking, and diabetes.
Each of them has a spouse and there is a good mutual relation.
Among the AD patients, some subjects have complex disorders
such as comorbid diabetes, depression, and overeating (Brownley
et al., 2015).
To avoid the interference of the experiences for playing a
GO game, none of them had ever played a GO game before
the study. Before game training, all subjects from GO-game
groups were invited to learn the rules for playing the game from
websites, such as http://en.wikipedia.org/wiki/GO_(game). All
participants were trained by a game player in the same club. After
mastering the basic rules, each person from GO-game groups
can ﬁnish the game as Figure 2 showed. In GO groups, two
partners were combined randomly. If one patient could not ﬁnd a
partner, he or she watched the game played by other participants.
Otherwise, he or she would play with one of GO-game staﬀ.
Neuropsychological Tests
According to Diagnostic and Statistical Manual of Mental
Disorders (DSM), all the cases were diagnosed by licensed
neurological physicians including neurological examination,
blood tests, and neuroimaging data (computed tomography or
magnetic resonance imaging). Clinical Dementia Rating (CDR)
scale is often used to detect memory and executive functions
(Inoue et al., 2012). Furthermore, CDR is used not only to detect
memory impairment but also to quantify dementia severity. CDR
is also used to assess domains of cognition (memory, orientation
and problem solving) and the domains of functions (community
aﬀairs, home, and hobbies and personal care) (Cedarbaum et al.,
2013). Furthermore, theMiniMental State Examination (MMSE)
has been widely used for testing memory problems. Clinicians
often diagnose dementia and assess its progression and severity
by MMSE scores.
Depression is a frequent condition for AD patients, so the
depressive severity was examined based on the Montgomery
and Asberg Depression Rating Scale (MADRS) (Alonzo et al.,
2013). There are 10 items for MADRS scoring from 0 to 60. The
severities of depression were regarded as severe, moderate and
mild based on diﬀerent cut-oﬀ scores (Birnbaum et al., 2009).
Furthermore, all participants was evaluated with the Kimberley
Indigenous Cognitive Assessment of Depression (KICA-Dep)
(Salvatore et al., 2013). There are 11 items for KICA-Dep, each
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FIGURE 1 | The flowchart of the study. LGGI, a long-time GO game intervention. SGGI, a short-time GO game intervention. Control group, without a GO game
intervention.
of which is assigned as from “never” to “sometimes,” “a lot” and
“all the time” based on a frequency scale.
Some AD patients suﬀer from anxiety disorder (Ramakers
et al., 2013; Mormont et al., 2014) and anxiety was measured
based on Hospital Anxiety and Depression Scale (HADS) (Hinz
et al., 2014). The scores of HADS are presented as from 0 to
21, and higher scores stand for more severe anxiety. General
functioning was evaluated by a Global Assessment of Functioning
(GAF) scale (Mello et al., 2007). Life quality was assessed using
RAND-36 (Mattila et al., 2012), which counts for wellbeing and
functioning in eight dimensions. Alexithymia is a psychological
problem andwas evaluated using the Toronto Alexithymia Scale–
20 (TAS-20) (Melin et al., 2010).
ELISA Analysis of BDNF
To determine serum levels of BDNF, 5ml of blood samples were
taken (8:00–11:00 a.m.) by venipuncture into a free-anticoagulant
vacuum tube at before and after 6-month follow-up. The blood
samples were centrifuged at 3000 g for 10min, and serum was
isolated and kept at −80◦C until next step. The serum levels of
BDNF were measured using a human BDNF ELISA kit (Adipo
Bioscience, Santa Clara, CA, USA).
Statistical Analyses
All statistical analyses were performed with a SPSS 20.0 package
(IBM China Company Limited, Beijing, China). The AD patients
were compared by t-tests between GO groups and the control
group without a GO intervention. One-Way ANOVA was used
to explore the eﬀect of a GO game on the levels of BDNF in AD
patients. Spearman’s rank correlation coeﬃcient was conducted
to identify the correlation between the depressive severity
(Montgomery-Asberg Depression Rating Scale or RAND-36)
and BDNF levels. There were statistically signiﬁcant diﬀerences
if P < 0.05.
Results
The Baseline Characters of AD Patients
All 147 AD patients had medical histories consistent with AD
and took neurological examinations (Supplemental Table 1).
Controls were matched well to AD patients by gender and
age at onset (P > 0.05). A previous report has found that
BMI is associated with the risk of AD (Besser et al., 2014). To
avoid the eﬀects of BMI on present results, all patients were
selected to guarantee that there were no statistically signiﬁcant
diﬀerences among three groups (P > 0.05) (Supplemental
Table 1). Diabetes is an increasing epidemic and aﬀects millions
of the elderly worldwide. The chronic disease also aﬀects brain
function and contributes to an AD risk (Butterﬁeld et al., 2014).
Similarly, high blood pressure and coronary heart disease are also
contributing factors for the development of AD (Qiu et al., 2006;
Lattanzi et al., 2014). Furthermore, cigarette smoking has been
reported to be also associated with incipient AD (Chang et al.,
2012). Alcohol drinking can impair brain function, and cause
dementia and geriatric cognitive disorders (Wiscott et al., 2001).
The patients with long-period education have better cognitive
functions than the AD patients with short-period education
(Pradier et al., 2014). Furthermore, the anterior temporal lobes
play an important role in melody recognition, and that music
can signiﬁcantly aﬀect AD patients (Johnson et al., 2011). To
avoid these interfering factors, all the elements were carefully
examined to exclude their eﬀects on ﬁnal results (Supplemental
Table 1). In neuropsychological tests, all AD patients had MMSE
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FIGURE 2 | GO game profile.
scores less than 26 and the CDR scale of 0.5 or over 0.5
(Supplemental Table 1). The results indicated that all AD subjects
had clinical dementia. Similarly, all AD patients had the similar
psychiatric test values and the prevalence of KICA-dep items
in AD patients among LGGI, SGGI, and control groups (P >
0.05) (Supplemental Table 1 and Table 1). Therefore, the baseline
characters of patients were basically similar among three groups.
Statistical Analyses for the Outcomes at 6-month
Follow-up
Statistical analyses showed that a GO-game intervention
signiﬁcantly decreased the mean score of MADRS of 4.72 (95%
CI, 0.69–9.12) compared with those in a control group after 6-
month follow-up (P < 0.05) (Supplemental Table 2). In the
similar way, a GO-game intervention also reduced mean score
of HADS of 1.75 (95% CI, 0.17–3.68) when compared with those
from controls (P < 0.05) (Supplemental Table 2). In contrast,
a GO-game intervention signiﬁcantly increased the mean score
of GAF of 4.95 (95% CI, −1.37–9.18) and RAND-36 of 4.61
(95% CI, −2.75–11.32) when compared with a control group
(P < 0.05) (Supplemental Table 2). For TAS-20, there was no
statistically signiﬁcant diﬀerence in three groups (P > 0.05)
(Supplemental Table 2). The results may be caused by alexithymic
personality traits, which are closely related with gender, advanced
age, educational level and social intelligence (Koelkebeck et al.,
2010).
A GO Game Improves the Symptoms of AD
The analysis for KICA-Dep items showed that GO game relieved
the symptoms of AD patients compared with those from a
control group (Table 1). In the 11 items of KICA-Dep, a control
group could not attenuate the symptoms of AD patients and
there was no statistically signiﬁcant diﬀerence for most items
(P > 0.05) except of two ones (Table 1). Comparatively, a
GO game ameliorated the symptoms of depression and there
were statistically signiﬁcant diﬀerences for most items (P <
0.05) except of two items (Table 1). After a 6-month GO-game
intervention, the severity of AD was decreased signiﬁcantly (P <
0.05) (Table 1).
The Levels of BDNF Are Negatively Related with
Stratification of CDR
When AD severity was stratiﬁed by CDR scales at onset (χ2 =
6.8, P = 0.03), signiﬁcant diﬀerences of BDNF levels were
observed in lower (CDR 0.5), middle (CDR 1), and higher CDR
(CDR 2+). There were statistically signiﬁcant diﬀerences for
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BDNF levels between CDR 0.5 and 2+ (P < 0.05). BDNF levels
were negatively related with CDR scales, suggested that low levels
of BDNF were related with AD risk since the BDNF levels were
higher in lower CDR scores compared to those in higher CDR
scores (χ2 = 214, P < 0.01) while CDR scores have been used to
evaluate the severity of AD (Clark et al., 2014).
Association between an AD Episode and the
Protein Levels of BDNF
Elevated levels of BDNF were related with a decrease in MADRS
scores and an increase in RAND-36 scales (P < 0.01). There was
a strong negative relationship between the severity of AD and the
levels of BDNF because the rho values were less than −0.5 based
on the calculation of Spearman’s rank correlation coeﬃcient.
A GO Game Enhances the Serum Protein Levels
of BDNF in AD Patients
The study consisted of 147 AD patients before and after 6-month
follow-up. The socio-demographic was list in Supplemental Table
1 and balanced based on age, gender, educational levels, life habits
and medicine therapy. The results showed that BDNF levels were
similar in three groups before GO game intervention. After 6-
month intervention, serumBDNF levels were signiﬁcantly higher
in subjects receiving SGGI and LGGI (respectively, 24.02 ± 7.16
and 28.88 ± 4.12 ng/ml, t = 0.345, P = 0.051) when compared
with controls (17.28 ± 7.75 ng/ml) (t = 3.423, P = 0.001)
(Figure 3). All these results implied that a GO game promotes
the production of BDNF.
Discussion
AGO game is very popular in China, Japan, and Korean, and can
be widely played. More importantly, a GO game has been proved
to be very interesting for its rich strategies with simple rules and
attracts many elderly adults. The game is more suitable to be
developed to prevent the progression of AD. We investigated the
eﬀects of the game on AD and related molecular mechanisms.
On the other hand, physical activities can certainly delay the loss
of autonomy in AD patients and are also useful strategies for
delaying the complications of AD (Rolland et al., 2000). During
the recruitment, some AD patients like physical exercises but
they dislike playing GO game. In the similar cases, some AD
patients like playing the game but they dislike physical exercises.
Only a few AD patients like playing a GO game and physical
exercises. The sample size will be a problem for considering both
physical exercises and a GO game. Furthermore, the eﬀects of
physical exercises on AD patients have been reported. Thus, we
only consider the eﬀects of a GO game on AD here. The patients
will be excluded if they dislike playing the game. Importantly, a
GO game showed eﬀective anti-depression results with few side
eﬀects. Meanwhile, we interpreted the possible outcome by using
GO-game-speciﬁc and computational methods with a particular
motivation to detect therapeutically-relevant phenomena.
The strength of the paper is its technique in clinical practice.
Furthermore, each person in GO groups could play the game
well with basic rules. On the other hand, the combination of
various techniques was utilized. Brain imaging and self-ratings,
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FIGURE 3 | Serum BDNF levels in control, LGGI and SGGI groups
before and after 6-month follow-up. Comparative analyses were carried
out using ANOVA followed by a Duncan test. Values were expressed as
mean ± SD. N = 49 cases in each group. The bars in the boxes were
average expression and the boxes represented 95% of the samples. The
error bars were above or below the boxes.
computational game analyses and psychiatric assessment was
undertaken, resulting in complementary and myriad measures
access to various underlying determinants of an intervention.
Some brain imaging techniques, such as fMRI and PET,
can provide distinct spatial information, but which cannot
provide time and event-related correlations. Depression has been
reported to be correlated with a hypo-activation of left brain
activity and a hypo-inactivation of right brain activity (Richieri
et al., 2012), which can be ameliorated with the time going after
playing the game.
MADRS is one of the most eﬀective tools for detecting the
depression in AD patients and higher MADRS score suggests
severe depression (Müller-Thomsen et al., 2005). We used the
MADRS to measure the changes of depression severity. The
results showed that a GO game signiﬁcantly decreased mean
score of MADRS of 4.72 (95% CI, 0.69–9.12) when compared
with controls after 6-month follow-up (P < 0.05, Supplemental
Table 2). HADS is also an important tool to detect the depression
of AD (Pietrzak et al., 2015), so we also measured the HADS
scores here. In the similar results, a GO game decreased the
mean score of HADS of 1.75 (95% CI, 0.17–3.68) when compared
with controls in the same period (P < 0.05, Supplemental
Table 2). Furthermore, KICA-Dep has been reported to very
useful for detecting the depressive symptoms in AD patients.
The results indicated that a GO game improved 9 of 11 items
of KICA-Dep compared with controls after 6-month follow-up
(Table 1). On the other hand, GAF has been used to evaluate the
overall improved quality of life in AD patients (Lu et al., 2006).
Thus, wemeasured GAF and found that a GO game increased the
mean score of GAF of 4.95 (95% CI, −1.37–9.18) and RAND-36
of 4.61 (95% CI, −2.75–11.32) when compared with those in a
control group after 6-month follow-up (P < 0.05, Supplemental
Table 2).
Although a GO game showed eﬀective results for ameliorating
the symptoms of AD, the molecular mechanism remains
unknown. Previous work demonstrates that AD patients have
reduced levels of BDNF in the brain and serum. Additionally,
animal-based studies also showed protective eﬀects of BDNF
against Amyloid beta-protein (Abeta)-induced neurotoxicity
(Psotta et al., 2015). Abeta1-42 exhibits neurotoxicity and induces
neural death. Abeta1-40 can inhibit the ﬁbril formation of
Abeta1-42 (Zou et al., 2003). In contrast, Abeta1-16, Abeta25-35,
and Abeta40-1 prevent neither the ﬁbril formation of Abeta1-
42 nor Abeta1-42-induced neural death. Here, we measured
serum levels of BDNF in AD patients and found that a GO
game increased serum BDNF levels in SGGI and LGGI groups
(24.02 ± 7.16 and 28.88 ± 4.12 ng/ml respectively, t = 0.345,
P = 0.051) compared those in controls (17.28± 7.75 ng/ml) (t =
3.423, P = 0.001) after 6-month follow-up. Furthermore, the
serum levels of BDNF showed a negative relation with MADRS
and a positive relation with RAND-36 scores (P < 0.01).
A GO game ameliorates AD patients by up-regulating BDNF
levels. Thus, A GO game is eﬀective to prevent the development
of AD.
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Alexithymia is considered for its defects in regulating feelings
(Goerlich et al., 2011) and typically co-occurs with depression
(Gilbert et al., 2014). However, alexithymia is a complex brain
disorder with a cluster of deﬁcits in the recognition (Reker et al.,
2010). Here we found that a GO gamewas not an eﬀective way for
the treatment of alexithymia compared with that from a control
group (P > 0.05) (Table 1). In any way, a GO game can improve
the life quality in other aspects (P < 0.05) (Supplemental
Table 2).
In addition, evoking and dealing with emotions is usually
related with a GO game, which ﬁt the treatment of emotional
disorders just like depression. Although all AD patients wanted
to learn and play a GO game before the study, someone
kept active exercises and a few kept passive exercises for
the game with time going. We found that most winners
were active for playing the game while a few losers were
passive for playing the game. We would let the game
trainers play with these passive losers and let them win
on purpose. Most of them could become active again for
playing the game ﬁnally. In order to gain an insight into the
eﬀectiveness of the game, we also aimed to develop novel
analytical methods for clinical purposes, such as kinematics,
electromyographic and electroencephalographic (EEG) data
(Barlaam et al., 2011). The new concept is also needed to
understand the mechanisms by studying symptoms, behaviors,
or biomarkers, which are diﬀerent to traditional classiﬁcation for
the mental disorders (Badcock and Hugdahl, 2014). Meanwhile,
the study will provide valuable information for the therapy of
depression.
Limitations
A GO game aﬀects the progression of depression but the
molecular mechanism remains unknown. Much evidence
indicates that chronic stress and low levels of BNDF are the key
causes of depression (Banerjee et al., 2014; Vásquez et al., 2014).
However, the clinical relevance of a GO game intervention and
the levels of BDNF remain unknown. Here, we ﬁrstly reported
that a GO game ameliorated the depression by aﬀecting the
serum levels of BDNF.We found the relationships between SGGI
or LGGI and levels of BDNF. The results showed that lower
concentration of BDNF might be speciﬁc for the depressive state
in AD patients. BDNF is a potential biomarker for adjuvant
diagnosis and therapy of an AD episode. However, further studies
are necessary to deﬁne a functional role of BDNF in preventing
the development of depression.
Certainly, the present trial still has its limitations in a statistical
sense. The sample size was suﬃcient to detect an eﬀect in the
primary outcome at 6-months, but not at longer period although
we found the eﬀect tended to persist. Second, the present trial
was the GO game intervention. It remained unknown whether
a long-term GO game was better than a short-term GO game.
At least, there are no reports showing such indication yet.
However, we still believe that a GO game intervention may
be more suitable for a few populations only received medicine
therapy.
Finally, a major problem with the design is that the control
group did not receive any treatment. Therefore, it is not possible
to know whether the changes reported are because the treatment
groups received attention from and interacted with colleagues
and staﬀ or because of the game itself. A “placebo” procedure
will be necessary to enable solid conclusions. Unfortunately, the
“placebo” group is hard to be designed because no game can
be matched GO game well according our experiences. Being
interesting is very important to play a game. Gomoku, also called
Five in a Row, can be played on a GO board. FromMay 6th, 2012
to August 12th, 2013, a total of 50 AD patients were recruited.
All the participants did not have the experiences of playing
Gomoku and showed interests for the game before the study.
However, more than 50% patients lost their passions for the game
after 2-month follow-up and the work was unavoidably stopped.
Fortunately, less than 10% patients lost enthusiasm for GO game
even after 6-month. Furthermore, these patients still could show
enthusiasm again for GO game when they won in subsequent
matches, which were designed on purpose by the GO game staﬀ.
We think that a GO game shows its beneﬁcial functions on
AD patients since the enthusiasm still can be maintained after
6-month follow-up.
Clinical and Mechanistic Implications
A GO game can improve the life quality of AD patients. None
complained of playing a GO game and no routine neurological
exam could identify any adverse eﬀect. Playing a GO game should
be developed a public activity since the game intervention can
reduce the symptoms of AD. Its mechanistic implication may
be that many strategies involve in the play and the number of
possible games is vast (there are about 10120 possible results for
playing the game), although the rules of game are very simple.
Given the substantial changes in the game, the game attracts an
ever-growing older population. Playing a simple and inexpensive
game can improve the cognitive functions of AD patients.
Millions of AD patients are looking for a technologically-oriented
game to enhance their cognitive skills, which can prevent the
development of AD.
In sum, a GO game is feasible and eﬀective to improve life
quality of AD patients by reducing their depression. A GO
game intervention reduces AD severity by increasing the level of
BDNF. Thus, a GO game should be developed as a new method
for the therapy of AD.
Acknowledgments
We are very grateful to all anonymous reviewers for their critical
and strategic comments, which have signiﬁcantly improved the
quality of the paper.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fnagi.
2015.00163
Frontiers in Aging Neuroscience | www.frontiersin.org 8 August 2015 | Volume 7 | Article 163
Lin et al. GO-game intervention on Alzheimer disease
References
Ahn, S. H., Choi, N. K., Kim, Y. J., Seong, J. M., Shin, J. Y., Jung, S. Y.,
et al. (2014). Drug persistency of cholinesterase inhibitors for patients with
dementia of Alzheimer type in Korea. Arch. Pharm. Res. 38, 1255–1262. doi:
10.1007/s12272-014-0500-8
Alonzo, A., Chan, G., Martin, D., Mitchell, P. B., and Loo, C. (2013). Transcranial
direct current stimulation (tDCS) for depression: analysis of response using
a three-factor structure of the Montgomery-Asberg depression rating scale.
J. Aﬀect. Disord. 150, 91–95. doi: 10.1016/j.jad.2013.02.027
Badcock, J. C., and Hugdahl, K. (2014). A synthesis of evidence on
inhibitory control and auditory hallucinations based on the Research
Domain Criteria (RDoC) framework. Front. Hum. Neurosci. 8:180. doi:
10.3389/fnhum.2014.00180
Banerjee, R., Hazra, S., Ghosh, A. K., and Mondal, A. C. (2014). Chronic
administration of bacopa monniera increases BDNF protein and mRNA
expressions: a study in chronic unpredictable stress induced animal model of
depression. Psychiatry Investig. 11, 297–306. doi: 10.4306/pi.2014.11.3.297
Barlaam, F., Descoins, M., Bertrand, O., Hasbroucq, T., Vidal, F., Assaiante,
C., et al. (2011). Time-Frequency and ERP Analyses of EEG to characterize
anticipatory postural adjustments in a bimanual load-lifting task. Front. Hum.
Neurosci. 5:163. doi: 10.3389/fnhum.2011.00163
Besser, L. M., Gill, D. P., Monsell, S. E., Brenowitz, W., Meranus, D. H., Kukull, W.,
et al. (2014). Body mass index, weight change, and clinical progression in mild
cognitive impairment and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 28,
36–43. doi: 10.1097/WAD.0000000000000005
Birnbaum, H., Kessler, R., Joish, V., Kelley, D., Ben-Hamadi, R., Hsieh, M., et al.
(2009). Healthcare resource utilization and costs of mild, moderate, and severe
depression in the workforce in the United States. Eur. Psychiatry 24, S614. doi:
10.1016/S0924-9338(09)70847-8
Boiocchi, C., Maggioli, E., Zorzetto,M., Sinforiani, E., Cereda, C., Ricevuti, G., et al.
(2013). Brain-derived neurotrophic factor gene variants and Alzheimer disease:
an association study in an Alzheimer disease Italian population. Rejuvenation
Res. 16, 57–66. doi: 10.1089/rej.2012.1381
Brownley, K. A., Boettiger, C. A., Young, L., and Cefalu, W. T. (2015). Dietary
chromium supplementation for targeted treatment of diabetes patients with
comorbid depression and binge eating. Med. Hypotheses 85, 45–48. doi:
10.1016/j.mehy.2015.03.020
Butterﬁeld, D. A., Di Domenico, F., and Barone, E. (2014). Elevated risk
of type 2 diabetes for development of Alzheimer disease: a key role for
oxidative stress in brain. Biochim. Biophys. Acta 1842, 1693–1706. doi:
10.1016/j.bbadis.2014.06.010
Cedarbaum, J. M., Jaros, M., Hernandez, C., Coley, N., Andrieu, S., Grundman,M.,
et al. (2013). Rationale for use of the Clinical Dementia rating sum of boxes as
a primary outcome measure for Alzheimer’s disease clinical trials. Alzheimer’s
Dement. 9, S45–S55. doi: 10.1016/j.jalz.2011.11.002
Chang, C. C., Zhao, Y., Lee, C. W., and Ganguli, M. (2012). Smoking, death, and
Alzheimer disease: a case of competing risks. Alzheimer Dis. Assoc. Disord. 26,
300–306. doi: 10.1097/WAD.0b013e3182420b6e
Clark, D. G., Kapur, P., Geldmacher, D. S., Brockington, J. C., Harrell, L., DeRamus,
T. P., et al. (2014). Latent information in ﬂuency lists predicts functional
decline in persons at risk for Alzheimer disease. Cortex 55, 202–218. doi:
10.1016/j.cortex.2013.12.013
Dysken, M.W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., et al.
(2014). Eﬀect of vitamin E and memantine on functional decline in Alzheimer
disease: the TEAM-AD VA cooperative randomized trial. JAMA 311, 33–44.
doi: 10.1001/jama.2013.282834
Evans, D. A., Morris, M. C., and Rajan, K. B. (2014). Vitamin E, memantine, and
Alzheimer disease. JAMA 311, 29–30. doi: 10.1001/jama.2013.282835
Fan, D., Li, J., Zheng, B., Hua, L., and Zuo, Z. (2014). Enriched Environment
Attenuates Surgery-Induced Impairment of Learning, Memory, and
Neurogenesis Possibly by Preserving BDNF Expression. Mol. Neurobiol.
doi: 10.1007/s12035-014-9013-1. [Epub ahead of print].
Gatz, M. (2005). Educating the brain to avoid dementia: can
mental exercise prevent Alzheimer disease? PLoS Med. 2:e7. doi:
10.1371/journal.pmed.0020007
Gilbert, P., McEwan, K., Catarino, F., Baião, R., and Palmeira, L. (2014). Fears of
happiness and compassion in relationship with depression, alexithymia, and
attachment security in a depressed sample. Br. J. Clin. Psychol. 53, 228–244.
doi: 10.1111/bjc.12037
Goerlich, K. S., Witteman, J., Aleman, A., and Martens, S. (2011). Hearing feelings:
aﬀective categorization of music and speech in alexithymia, an ERP study. PLoS
ONE 6:e19501. doi: 10.1371/journal.pone.0019501
Gregori, M., Masserini, M., and Mancini, S. (2015). Nanomedicine for the
treatment of Alzheimer’s disease. Nanomedicine (Lond.) 10, 1203–1218. doi:
10.2217/nnm.14.206
Hamilton, A., Zamponi, G. W., and Ferguson, S. S. (2015). Glutamate receptors
function as scaﬀolds for the regulation of beta-amyloid and cellular prion
protein signaling complexes. Mol. Brain 8, 18. doi: 10.1186/s13041-015-
0107-0
Hinz, A., Finck, C., Gómez, Y., Daig, I., Glaesmer, H., and Singer, S. (2014). Anxiety
and depression in the general population in Colombia: reference values of
the Hospital Anxiety and Depression Scale (HADS). Soc. Psychiatry Psychiatr.
Epidemiol. 49, 41–49. doi: 10.1007/s00127-013-0714-y
Hultsch, D. F., Hertzog, C., Small, B. J., and Dixon, R. A. (1999). Use it or lose
it: engaged lifestyle as a buﬀer of cognitive decline in aging? Psychol. Aging 14,
245–263. doi: 10.1037/0882-7974.14.2.245
Inoue, K., Meguro, K., Akanuma, K., Meguro, M., Yamaguchi, S., and Fukuda, H.
(2012). Impaired memory and executive function associated with decreased
medial temporal and prefrontal blood ﬂow in Clinical Dementia Rating 0.5
status: the Osaki−Tajiri project. Psychogeriatrics 12, 27–33. doi: 10.1111/j.1479-
8301.2011.00384.x
Jain, S., Farooq, S. J., and Gottlob, I. (2008). Resolution of superior
oblique myokymia with memantine. J. AAPOS 12, 87–88. doi:
10.1016/j.jaapos.2007.07.007
Johnson, J. K., Chang, C. C., Brambati, S. M., Migliaccio, R., Gorno-Tempini,
M. L., Miller, B. L., et al. (2011). Music recognition in frontotemporal lobar
degeneration and Alzheimer disease. Cogn. Behav. Neurol. 24, 74–84. doi:
10.1097/WNN.0b013e31821de326
Kim, S. H., Han, D. H., Lee, Y. S., Kim, B. N., Cheong, J. H., and Han, S. H. (2014).
Baduk (the Game of GO) Improved Cognitive Function and Brain Activity in
Children with Attention Deﬁcit Hyperactivity Disorder. Psychiatry Investig. 11,
143–151. doi: 10.4306/pi.2014.11.2.143
Koelkebeck, K., Pedersen, A., Suslow, T., Kueppers, K. A., Arolt, V., and Ohrmann,
P. (2010). Theory of Mind in ﬁrst-episode schizophrenia patients: correlations
with cognition and personality traits. Schizophr. Res. 119, 115–123. doi:
10.1016/j.schres.2009.12.015
Lattanzi, S., Viticchi, G., Falsetti, L., Buratti, L., Luzzi, S., Provinciali,
L., et al. (2014). Visit-to-Visit Blood Pressure Variability in
Alzheimer Disease. Alzheimer Dis. Assoc. Disord. 28, 347–351. doi:
10.1097/WAD.0000000000000040
Lee, B., Park, J. Y., Jung, W. H., Kim, H. S., Oh, J. S., Choi, C. H., et al. (2010).
White matter neuroplastic changes in long-term trained players of the game of
"Baduk" (GO): a voxel-based diﬀusion-tensor imaging study. Neuroimage 52,
9–19. doi: 10.1016/j.neuroimage.2010.04.014
Lee, S. T., Chu, K., Jung, K. H., Kim, J. H., Huh, J. Y., Yoon, H., et al. (2012). miR-
206 regulates brain-derived neurotrophic factor in Alzheimer disease model.
Ann. Neurol. 72, 269–277. doi: 10.1002/ana.23588
Leikin, J. B., Braund, V., and DesLauris, C. (2014). Cholinergic symptoms with low
serum cholinesterase from therapeutic cholinesterase inhibitor toxicity. Am. J.
Emerg. Med. 32, 815. e813–814. doi: 10.1016/j.ajem.2013.12.048
Lu, P. H., Masterman, D. A., Mulnard, R., Cotman, C., Miller, B., Yaﬀe, K., et al.
(2006). Eﬀects of testosterone on cognition and mood in male patients with
mild Alzheimer disease and healthy elderly men. Arch. Neurol. 63, 177–185.
doi: 10.1001/archneur.63.2.nct50002
Mattila, K., Lahtela, M., and Hynynen, M. (2012). Health-related quality of life
following ambulatory surgery procedures: assessment by RAND-36. BMC
Anesthesiol. 12:30. doi: 10.1186/1471-2253-12-30
Melin, E. O., Thulesius, H. O., and Persson, B. A. (2010). Aﬀect School
for chronic benign pain patients showed improved alexithymia
assessments with TAS-20. Biopsychosoc. Med. 4:5. doi: 10.1186/1751-
0759-4-5
Mello, A. F., Blay, S. L., and Kohn, R. (2007). Global Assessment of
Relational Functioning Scale (GARF): a validity study in patients with
recurrent major depression in Brazil. Transcult. Psychiatry 44, 55–64. doi:
10.1177/1363461507074969
Frontiers in Aging Neuroscience | www.frontiersin.org 9 August 2015 | Volume 7 | Article 163
Lin et al. GO-game intervention on Alzheimer disease
Mormont, E., Jamart, J., and Jacques, D. (2014). Symptoms of depression and
anxiety after the disclosure of the diagnosis of Alzheimer disease. J. Geriatr.
Psychiatry Neurol. 27, 231–236. doi: 10.1177/0891988714532021
Müller-Thomsen, T., Arlt, S., Mann, U., Mass, R., and Ganzer, S. (2005). Detecting
depression in Alzheimer’s disease: evaluation of four diﬀerent scales.Arch. Clin.
Neuropsychol. 20, 271–276. doi: 10.1016/j.acn.2004.03.010
Palacios, R. (2013). Post-trial access and the new version of the Declaration of
Helsinki. Colomb Med (Cali.) 44, 206–207.
Pietrzak, R. H., Lim, Y. Y., Neumeister, A., Ames, D., Ellis, K. A., Harrington,
K., et al. (2015). Amyloid-beta, anxiety, and cognitive decline in preclinical
Alzheimer disease: a multicenter, prospective cohort study. JAMA Psychiatry
72, 284–291. doi: 10.1001/jamapsychiatry.2014.2476
Pradier, C., Sakarovitch, C., Le Duﬀ, F., Layese, R., Metelkina, A., Anthony, S., et al.
(2014). The mini mental state examination at the time of Alzheimer’s disease
and related disorders diagnosis, according to age, education, gender and place
of residence: a cross-sectional study among the French National Alzheimer
database. PLoS ONE 9:e103630. doi: 10.1371/journal.pone.0103630
Provencher, V., Bier, N., Audet, T., and Gagnon, L. (2009). Long-term eﬀect
of a cognitive intervention on learning and participation in a signiﬁcant
leisure activity in early dementia of Alzheimer type: a case study. Psychol.
Neuropsychiatr. Vieil. 7, 131–140. doi: 10.1684/pnv.2009.0166
Psotta, L., Rockahr, C., Gruss, M., Kirches, E., Braun, K., Lessmann, V.,
et al. (2015). Impact of an additional chronic BDNF reduction on learning
performance in an Alzheimer mouse model. Front. Behav. Neurosci. 9:58. doi:
10.3389/fnbeh.2015.00058
Qiu, C., Bäckman, L., Winblad, B., Aguero-Torres, H., and Fratiglioni, L. (2001).
The inﬂuence of education on clinically diagnosed dementia incidence and
mortality data from the Kungsholmen Project. Arch. Neurol. 58, 2034–2039.
doi: 10.1001/archneur.58.12.2034
Qiu, C., Winblad, B., Marengoni, A., Klarin, I., Fastbom, J., and Fratiglioni,
L. (2006). Heart failure and risk of dementia and Alzheimer disease: a
population-based cohort study. Arch. Intern. Med. 166, 1003–1008. doi:
10.1001/archinte.166.9.1003
Ramakers, I. H., Verhey, F. R., Scheltens, P., Hampel, H., Soininen, H., Aalten,
P., et al. (2013). Anxiety is related to Alzheimer cerebrospinal ﬂuid markers
in subjects with mild cognitive impairment. Psychol. Med. 43, 911–920. doi:
10.1017/S0033291712001870
Reker, M., Ohrmann, P., Rauch, A. V., Kugel, H., Bauer, J., Dannlowski, U., et al.
(2010). Individual diﬀerences in alexithymia and brain response to masked
emotion faces. Cortex 46, 658–667. doi: 10.1016/j.cortex.2009.05.008
Richieri, R., Boyer, L., Padovani, R., Adida, M., Colavolpe, C., Mundler, O.,
et al. (2012). Equivalent brain SPECT perfusion changes underlying
therapeutic eﬃciency in pharmacoresistant depression using either
high-frequency left or low-frequency right prefrontal rTMS. Prog.
Neuropsychopharmacol. Biol. Psychiatry 39, 364–370. doi: 10.1016/j.pnpbp.
2012.07.012
Rolland, Y., Rival, L., Pillard, F., Lafont, C., Rivére, D., Albaréde, J., et al. (2000).
Feasibility [corrected] of regular physical exercise for patients with moderate to
severe Alzheimer disease. J. Nutr. Health Aging 4, 109–113.
Rossom, R., and Adityanjee, Dysken, M. (2004). Eﬃcacy and tolerability of
memantine in the treatment of dementia. Am. J. Geriatr. Pharmacother. 2,
303–312. doi: 10.1016/j.amjopharm.2004.12.006
Salvatore, P., Baldessarini, R. J., Khalsa, H. M., Amore, M., Di Vittorio, C., Ferraro,
G., et al. (2013). Predicting diagnostic change among patients diagnosed with
ﬁrst-episode DSM-IV-TR major depressive disorder with psychotic features.
J. Clin. Psychiatry 74, 723–731. doi: 10.4088/JCP.12m08328
Sawada, A., Hara, K., Futa, R., and Ogata, H. (1971). Pressure-lowering eﬀect of
a new cholinesterase inhibitor, Ubretid on glaucoma. Nihon Ganka Kiyo 22,
676–682.
Tamaoka, A. (2011). Alzheimer’s disease: deﬁnition and National Institute of
Neurological and Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-ADRDA). Nippon.
Rinsho 69(Suppl. 10), 240–245.
van Beek, A. H., Sijbesma, J. C., Jansen, R. W., Rikkert, M. G., and Claassen,
J. A. (2010). Cortical oxygen supply during postural hypotension is further
decreased in Alzheimer’s disease, but unrelated to cholinesterase-inhibitor use.
J. Alzheimers. Dis. 21, 519–526. doi: 10.3233/JAD-2010-100288
Vásquez, C. E., Riener, R., Reynolds, E., and Britton, G. B. (2014). NMDA
receptor dysregulation in chronic state: a possible mechanism underlying
depression with BDNF downregulation. Neurochem. Int. 79C, 88–97. doi:
10.1016/j.neuint.2014.09.007
Villoslada, P., Arrondo, G., Sepulcre, J., Alegre, M., and Artieda, J. (2009).
Memantine induces reversible neurologic impairment in patients with MS.
Neurology 72, 1630–1633. doi: 10.1212/01.wnl.0000342388.73185.80
Voineskos, A. N., Lerch, J. P., Felsky, D., Shaikh, S., Rajji, T. K., Miranda, D.,
et al. (2011). The brain-derived neurotrophic factor Val66Met polymorphism
and prediction of neural risk for Alzheimer disease. Arch. Gen. Psychiatry 68,
198–206. doi: 10.1001/archgenpsychiatry.2010.194
Wiscott, R., Kopera-Frye, K., and Seifert, L. (2001). Possible consequences of social
drinking in the early stages of Alzheimer disease. Geriatr Nurs. 22, 100–104;
quiz 105. doi: 10.1067/mgn.2001.115201
Xiao, Q., Wang, C., Li, J., Hou, Q., Li, J., Ma, J., et al. (2010). Ginkgolide B protects
hippocampal neurons from apoptosis induced by beta-amyloid 25-35 partly
via up-regulation of brain-derived neurotrophic factor. Eur. J. Pharmacol. 647,
48–54. doi: 10.1016/j.ejphar.2010.08.002
Zhang, R., Wang, Z., Howson, P. A., Xia, Z., Zhou, S., Wu, E., et al. (2012).
Smilagenin attenuates beta amyloid (25-35)-induced degeneration of neuronal
cells via stimulating the gene expression of brain-derived neurotrophic factor.
Neuroscience 210, 275–285. doi: 10.1016/j.neuroscience.2012.03.017
Zou, K., Kim, D., Kakio, A., Byun, K., Gong, J. S., Kim, J., et al. (2003). Amyloid
beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42
in culture and in rat brain. J. Neurochem. 87, 609–619. doi: 10.1046/j.1471-
4159.2003.02018.x
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Lin, Cao and Gao. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 10 August 2015 | Volume 7 | Article 163
